Endocrine abnormality in paraneoplastic syndrome.
cytokines
endocrine
hormones
paraneoplastic syndrome
peptides
pituitary autoimmunity
Journal
Best practice & research. Clinical endocrinology & metabolism
ISSN: 1878-1594
Titre abrégé: Best Pract Res Clin Endocrinol Metab
Pays: Netherlands
ID NLM: 101120682
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
pubmed:
15
2
2022
medline:
31
5
2022
entrez:
14
2
2022
Statut:
ppublish
Résumé
Paraneoplastic syndromes denote rare but notable phenomena caused by the tumour mediated release of bioactive substances. Peptide and non-peptide hormone causes are explored with a particular focus on pathogenesis, symptoms, diagnosis and treatment. Early detection and management of paraneoplastic syndromes can improve morbidly and mortality; definitive treatment remains effective surgical or anti-tumour therapies. Pituitary autoimmunity may provide a novel presentation of paraneoplastic syndromes for which further research is warranted.
Identifiants
pubmed: 35153144
pii: S1521-690X(22)00008-2
doi: 10.1016/j.beem.2022.101621
pii:
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101621Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors of this manuscript have nothing to declare.